Home > Newsletters > Drug Industry Daily > BMS’ Experimental Liver Cancer Compound Fails Again in Late-Stage Trial
Drug Industry Daily
July 23, 2012 | Vol. 11 No. 143
BMS’ Experimental Liver Cancer Compound Fails Again in Late-Stage Trial
An experimental liver cancer treatment from Bristol-Myers Squibb (BMS) took another hit as it failed to match Bayer and Onyx Pharmaceuticals’ Nexavar as a first-line treatment in a Phase III trial.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.